SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK trial met its primary endpoints for Zenkuda and tabirafusp-ted in wet AMD, with Zenkuda showing six-month dosing durability for many patients and a planned FDA filing. Traders celebrated the data-driven surge and speculated about a short squeeze, while others warned of profit-taking, potential dilution, and the remaining need for FDA approval.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rally and surging volume are being linked by traders to IBM-related enterprise AI and digital-identity developments involving Hedera, alongside its broader AI-partner story. Others say the catalyst is unclear and view the move as momentum or a possible short squeeze, with debate over whether gains will hold or invite profit-taking.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

CEO CJ Desais abrupt departure for a senior role at Meta, shortly before MongoDBs investor day, has driven a sharp selloff and focused attention on leadership and execution uncertainty. Traders are divided between viewing the move as an overreactionpointing to former CEO Dev Ittycherias return and reaffirmed guidanceand worrying about the abrupt transition and its timing.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants selection by The Clearing House for its on-chain money initiative is driving attention, with traders framing the deal as a sign of growing bank adoption and renewed interest in the tokens limited supply. The sharp rally has prompted profit-taking and volatility, while some traders question whether the enterprise deal will create direct demand for QNT itself.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the Trump administration may ease sanctions and release frozen Iranian assets in exchange for nuclear progress drove sharp, headline-led swings in SPY. Traders debated whether the reports signaled a credible deal or were unconfirmed optimism, while some pointed to persistent oil and Treasury-yield pressure.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius U.S. defense grant to convert an existing battery line for high-energy-density drone cells is driving attention, with bulls viewing it as validation and a path to domestic production scale. Traders are frustrated that the initial rally faded, while others note the facility is years from completion and the grant is not a customer order or revenue, amid broader market pressure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

CLFs sharp selloff is being tied by traders to the announced plan for a large Mesabi Metallics steel plant in Iowa, with concerns about competition and possible challenges to CLFs Minnesota leases. Others doubt the project will proceed without financing and approvals, and attribute the decline to short selling rather than a change in fundamentals.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is drawing attention after promising VK2735 weight-loss and maintenance data was followed by a large stock-and-convertible offering, which traders say erased momentum and raised concerns about dilution and managements timing. Bulls see the data and added funding as support for the obesity-drug pipeline, while bears point to the financing overhang and a potentially long wait for further catalysts; buyout talk remains speculative.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp move toward the $9 area has fueled talk of short covering and a possible squeeze, though traders disagree on whether the price action is lasting or another brief swing. Speculation about upcoming ANKTIVA newsparticularly international expansion and the FDAs papillary bladder-cancer reviewis adding interest, but no new catalyst is confirmed in the discussion.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Upbeat wet-AMD pipeline updates from Kodiak and 4D Molecular Therapeutics have heightened competition concerns and coincided with OCULs sharp selloff. Traders are divided: some worry rivals raise the bar for AXPAXLI, while others argue its durability data and FDA-aligned filing path remain differentiators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch

Mercks partnership with Moderna is drawing attention after their personalized cancer vaccine plus Keytruda met Phase 3 recurrence-free and distant-metastasis-free survival endpoints in melanoma, prompting optimism about the oncology pipeline and potential relevance beyond melanoma. Traders also question whether the early results justify the enthusiasm, noting that detailed data and the broader commercial opportunity remain uncertain.

FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor

(RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor...

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (SciBrunch), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.Evidence continues...

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Equity

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years

Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.0% on an annualized basis producing an average annual return of 15.2%. Currently, Merck & Co has a market capitalization of $364.51read more...

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Mercks (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer...

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

U.S. FDA Approves WELIREG (belzutifan) Plus LENVIMA (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG (belzutifan), Mercks first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, plus LENVIMA...

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?

Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Bearish Sentiment

Track MRK stock price, charts, news and real-time market activity on Stocktwits. Join the MRK message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Merck & Co Inc stock.

MRK Stock Price Today - Merck & Co Inc News, Charts, Retail Sentiment

Iran/Middle East

Tariffs/trade policy

Economy/the $5K dividend

Something else entirely

President Trump is set to make an announcement from the Oval Office at 2pm EST today, with the White House keeping the topic under wraps. What do you think it&#39;s about? Drop a comment with your prediction.

Stocktwits

President Trump is set to make an announcement from the Oval Office at 2pm EST today, with the White House keeping the topic under wraps. What do you think it's about? Drop a comment with your prediction.

MRK Merck & Co Inc